ZyVersa Therapeutics, Inc.
ZVSA
$0.6794
-$0.0306-4.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 61.81% | -36.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 66.69% | -43.31% | |||
| Operating Income | -66.69% | 43.31% | |||
| Income Before Tax | -58.41% | 40.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -58.75% | 40.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -58.75% | 40.79% | |||
| EBIT | -66.69% | 43.31% | |||
| EBITDA | -66.55% | 43.27% | |||
| EPS Basic | -1.74% | 70.61% | |||
| Normalized Basic EPS | -1.52% | 70.55% | |||
| EPS Diluted | -1.74% | 70.61% | |||
| Normalized Diluted EPS | -1.52% | 70.55% | |||
| Average Basic Shares Outstanding | 56.02% | 101.47% | |||
| Average Diluted Shares Outstanding | 56.02% | 101.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||